Perrigo has launched Naproxen Sodium Soft Gels and, via its licensor and supplier Synthon, levocetirizine allergy tablets.


Perrigo, Aleve, Xyzal, generic, Naproxen Sodium Soft Gels, analgesic, Aleve Liquid Gels, Bayer HealthCare, levocetirizine, UCB/Sepracor, allergy tablets, Joseph Papa










































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Perrigo rolls out generics for Aleve, Xyzal

November 29th, 2010

ALLEGAN, Mich. – Perrigo has launched Naproxen Sodium Soft Gels and, via its licensor and supplier Synthon, levocetirizine allergy tablets.

The company said Monday that the Naproxen Sodium Soft Gels are the generic equivalent of Bayer HealthCare's Aleve Liquid Gels (220 mg), an over-the-counter analgesic.

Perrigo added that it believes it's the first company to market a store-brand version of this product and reported that Aleve Liquid Gels have annual sales of about $80 million, according to SymphonyIRI Group data.

Also on Monday, Perrigo announced that its licensor and supplier Synthon has received final approval from the Food and Drug Administration for levocetirizine tablets, a generic version of Xyzal tablets from UCB/Sepracor, which is marketed in the United States by Sanofi-Aventis.

Perrigo said it has the exclusive rights from Synthon to sell and distribute the product in the United States. The Synthon product is the only approved generic product having a label containing all indications as the brand product and is entitled to 180 days of exclusivity for a product labeled for both allergy and hives, according to the company.

Levocetirizine tablets are indicated for the treatment of indoor and outdoor allergies. According to Wolters Kluwer Health data, sales for Xyzal Tablets for the 12-month period ended September 2010 were $224 million.

"This is a terrific example of Perrigo leveraging its strong partnerships in bringing new products to market," Perrigo chairman and chief executive officer Joseph Papa stated. "We are excited to see the continued expansion of our generic Rx portfolio of products."

Advertisement